TP53 and neoplasm: Second, although we used WES and gene expression data from clinically similar patients with untreated localized prostate cancer from the TCGA to validate the link between biallelic losses to PTEN and TP53 with activation of TGF-β signaling, we could not identify a appropriate validation cohort of tumor biopsies with paired WES and gene expression data from patients treated with EBRT ± ADT.